Stockreport

Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China

Intellia Therapeutics, Inc.  (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview
PDF CAMBRIDGE, Mass., June 19, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially cur [Read more]